Vital expects ~$140m property revaluation gain for 1H FY22

MKTUPDTE
Thu, Dec 16 2021 10:18 am

NorthWest Healthcare Properties Management Limited (the Manager), as manager of Vital Healthcare Property Trust (Vital), expects Vital to record a property revaluation gain of approximately $140m for the six months ending 31 December 2021 with 80% of the portfolio (by value) independently valued. This preliminary draft revaluation gain represents a 5.3% increase since 30 June 2021 and reduces pro-forma LVR by 1.6%.

At 31 December 2021 Vital's property portfolio is anticipated to be valued at approximately $2.9b , 10% above 30 June 2021. The property portfolio weighted average capitalisation rate is approximately 4.66%, reflecting approximately 22 basis points of compression over the six-month period.

Vital's Fund Manager, Aaron Hockly, said:

" Investor appetite for quality Australian and New Zealand healthcare property remains strong demonstrated by several recent and anticipated transactions. Investors are particularly attracted to the sector's relatively low risk and low volatility."

The preliminary draft revaluation gain referred to above is subject to finalisation and audit and could be revised up or down. Final audited valuations will be confirmed when Vital's half year results are released on 24 February 2022.

FY22 market guidance remains at least 11.80 cpu in AFFO (2% above FY21) and 9.5 cpu in unitholder distributions (7% above FY21).

– ENDS –

ENQUIRIES

Aaron Hockly
Fund Manager, Vital Healthcare Property Trust
Tel 09 973 7301, Email [email protected]

Michael Groth
Chief Financial Officer, NorthWest Healthcare Properties Management Limited
Tel +61 409 936 104, Email [email protected]


Announcement PDF


Markets News

Markets

The ‘crack cocaine’ of the stock market

Gamblers Anonymous meetings are filling up with people hooked on trading and betting.

The ‘crack cocaine’ of the stock market
Markets

The wildest, weirdest stock-market prices we’ve ever seen

Here’s a tour through history’s most entertaining price anomalies.

The wildest, weirdest stock-market prices we’ve ever seen